Aim | Measures |
---|---|
Safety of IV therapy with autologous BM-derived MSC in RRMS, SPMS, and PPMS subjects | Number and severity of AEs within each treatment arm |
Activity of autologous BM-derived MSCs in MS subjects | Reduction compared to placebo in the total number of contrast-enhancing lesions (GEL) at MRI acquired on conventional MRI scans (minimum magnetic field intensity 1.5 T) over 24 weeks |